ChiCTR2100044339.
| Methods | Trial design: randomised, parallel study Trial registration number: ChiCTR2100044339 Country: China Outpatient or hospital: Shaanxi Traditional Chinese Medicine Hospital ‐ Tertiary Date trial conducted: from April 2021 Duration of trial participation: not reported Inclusion criteria: · Diagnosis of AD according to Hanifin and Rajka criteria · SCORAD score ≤ 40 · Aged between 7 and 60 years · Participant or guardian has signed the informed consent form. Exclusion criteria: · Severe primary diseases, such as cardiovascular disease, respiratory diseases, liver and kidney disease, blood system diseases, tumours and mental illness · Known experimental drug allergies · Abnormal clinical values · Pregnancy and breastfeeding or planning to get pregnant within 3 months · In the range of at least 4 weeks using systemic immunomodulatory or immunosuppressive agents. In the range of at least 2 weeks using systemic or local antibiotics. In the range of at least 2 weeks using antihistamines. In the range of at least 2 weeks using PUVA, UVA or UVB. · In the range of at least 2 weeks of local application of tacrolimus or glucocorticoids. · Participating in other clinical trials or have participated in other clinical trials within 1 month. · Other reasons the researchers considered unsuitable for inclusion. Additional design details: none |
| Participants | Total number randomised: not reported Age: 7 to 60 years Sex: both Ethnicity, duration of eczema: not reported Severity of eczema: SCORAD score ≤ 40 Body site, number of withdrawals: not reported Notes: none |
| Interventions | Run‐in details: not reported Intervention: Taxisan · Concurrent treatment: not reported · Other key information: none Comparator: vaseline · Concurrent treatment: not reported · Other key information: none Concurrent treatments received alongside both intervention and comparator: not reported Notes: none |
| Outcomes | · Scoring Atopic Dermatitis Index · VAS · IGA · DLQI · Colonisation of Staphylococcus aureus |
| Notes | Funding source: Xi'an Municipal Bureau of Science and Technology Declarations of interest: not declared Original language of publication: English Other: unclear if the intervention was an anti‐inflammatory |